Compound Profile
CJC 1295
GHRH analog peptide
CJC 1295 is a synthetic growth hormone releasing hormone (GHRH) analog engineered for a longer half life than natural GHRH, commonly combined with Ipamorelin in gray market protocols; its GH/IGF 1 mechanism has early pharmaceutical development data behind it, but no FDA approval and an uncertain compounding pathway.
Review needed — Review before use if any apply: Pregnancy/Breastfeeding, Uncontrolled Diabetes, Unsupervised RUO Product Use Without Physician Oversight. Details
At a glance
From this profile's structured data- Evidence
- Grade D
- Profile context
- GHRH Receptor Agonism, DAC Albumin-Binding Half-Life Extension, Downstream IGF-1 Elevation
Next stepsWhere to go next — guides & comparisons
Continue reading
- If you want to browse more compounds → All compounds
Unapproved compound: significant safety uncertainty
CJC-1295 is not FDA-approved for human use. FDA’s current compounding safety material describes limited clinical data and reports serious adverse events, including increased heart rate and a systemic vasodilatory reaction, associated with CJC-1295.
- Do not treat a prior Category 1/2 nomination or withdrawal as an FDA approval decision.
- Long-term human safety and efficacy are not established.
- A research-use label does not establish FDA-reviewed identity, quality, safety, or effectiveness for human use.
Regulatory status
2026 federal and state regulatory context
Sellable only as research use only (RUO) product; compounding pharmacy pathway is uncertain and not scheduled for near term PCAC review.
Regulatory changelog
- 2023 04/2026: FDA Category 2 restricted (503A bulk substances). 2026 04: Removed from Category 2 following nomination withdrawal (gray zone, not Category 1). Not included on the July 23 24, 2026 PCAC review agenda (which covers BPC 157, KPV, TB 500, MOTS C, Emideltide/DSIP, Semax, and Epitalon).
Quick stats
- Evidence level
- Preliminary evidence
- Typical onset
- Varies by prep
- Safety rating
- Review needed: Safety review pending
- Best for
- GHRH Receptor Agonism, DAC Albumin Binding Half Life Extension, Downstream IGF 1 Elevation
- Avoid / review if
- Pregnancy/Breastfeeding, Uncontrolled Diabetes, Unsupervised RUO Product Use Without Physician Oversight
Safety
Safety & Cautions
Review before use if any apply: Pregnancy/Breastfeeding, Uncontrolled Diabetes, Unsupervised RUO Product Use Without Physician Oversight.
High caution
Caution level: High. Multiple caution categories apply, or the record uses avoid/contraindication language.
- Interaction-AwareMedication or interaction context is explicitly noted.
- Hormonal Activity ContextHormone-adjacent wording is present and should be interpreted carefully.
- Pregnancy/Breastfeeding CautionPregnancy or breastfeeding caution language is present.
Evidence-based safety
Caution when combined
Severity and certainty are shown separately. A high-priority caution can still be theoretical: these pairings are screened from shared contraindication mechanisms and are not automatically documented clinical interactions. Provenance identifies the source fields that produced each flag; it does not upgrade the certainty of the pairwise claim.
Moderate Caution
110 flagged pairingsBlood-sugar lowering
Moderate Caution
110 flagged pairingsBlood-sugar lowering
Representative pairings are shown below. Large mechanism groups are intentionally summarized to keep profiles focused and crawl-efficient.
Data provenance recorded for 110 of 110 pairings in this mechanism group.
- Acarbose — Theoretical interaction certainty
- ajoene — Theoretical interaction certainty
- Allicin — Theoretical interaction certainty
- Aloe Vera — Theoretical interaction certainty
- Alpha-Lipoic Acid — Theoretical interaction certainty
- American Ginseng Extract — Theoretical interaction certainty
- Andrographis — Theoretical interaction certainty
- Anemarrhena Asphodeloides — Theoretical interaction certainty
- Tarragon — Theoretical interaction certainty
- Ashoka — Theoretical interaction certainty
- Astragalus — Theoretical interaction certainty
- Astragalus Membranaceus — Theoretical interaction certainty
+98 more pairings share this mechanism. Use the Safety Checker to review a specific combination.
Evidence Summary
Profile-wide ·D PreliminaryEvidence lens
Early signal that needs stronger human replication before practical claims.
Human clinical evidence: Not the primary signal
Mechanistic / preclinical: Mechanism mapped — GHRH Receptor Agonism · DAC Albumin Binding Half Life Extension · Downstream IGF 1 Elevation
Research maturity: Theoretical / mechanistic research — Mechanistic or unresolved evidence is kept separate from established human outcomes.
Safety boundary: Safety note available — Review before use if any apply: Pregnancy/Breastfeeding, Uncontrolled Diabetes, Unsupervised RUO Product Use Without Physician Oversight.
Confidence estimate based on the design quality and consistency of published clinical trials.
CJC 1295 has a preliminary evidence rating.
How evidence grades work
Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.
- Strong
- Multiple RCTs, consistent direction, adequate effect size
- Moderate
- Some RCTs or consistent observational data in humans
- Preliminary / Mixed
- Animal or in-vitro only, or conflicting human data
- Traditional / Theoretical
- Traditional use only; no controlled human trials
How CJC 1295 Works
Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.
Mechanism Pathway — How CJC 1295 Works
Dosing
- No standardized dose
- No established consumer dosing protocol; see full guide article for regulatory and safety context.
Mechanisms & biological pathways
Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.
- GHRH Receptor Agonism
- DAC Albumin Binding Half Life Extension
- Downstream IGF 1 Elevation
- Growth Hormone Axis
- IGF 1 Signaling
Compare & Sourcing
Compare side-by-side tradeoffs or verify active marker guidelines.
Free safety checklist
Get the CJC 1295 evidence notes
Occasional research updates, safety context, and product-quality checks for supplement decisions.
We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.
Sourcing options disabled for safety
Direct product recommendations and affiliate links are suppressed for this compound due to its high caution or needs-review safety classification.
Evaluate the safety checks, contraindications, and potential medication interactions above under clinician supervision before use.
Safety first · Harm reduction
This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.
Learn how we evaluate confidence, safety, and intensity on the methodology page.
Editorial Review
Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.
Help improve this profile
Was this useful for your research?
These controls record only the page and the structured choice you make when analytics consent is enabled. Please don’t include personal medical information in research requests.
Was this evidence summary clear?
Did you find what you were researching?
Compound profile context
How to interpret CJC 1295
CJC 1295 compound profile with evidence context, key research topics, source notes, safety context, and references presented in an evidence-first format. Use this compound profile to understand mechanism, evidence quality, and practical safety context before comparing products or building a stack. A biochemical pathway connection can be useful for discovery, but it is not the same as proven benefit in humans.
When reviewing CJC 1295, separate the active molecule from the product category around it. Dose form, absorption, extract standardization, medication interactions, and individual sensitivity can change the real-world risk-benefit picture.
For supplement planning, avoid combining multiple compounds with overlapping sedating, stimulating, serotonergic, blood-pressure, anticoagulant, or liver-metabolism effects unless a qualified clinician has reviewed the context.